==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1043 which contains 11 entries.


Entry 1
(1) Primary information
ID1305
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution110 to 127 mL/kg [pediatric patients]
ClearanceN.A.
CategoriesGout Suppressants
Patents NumberCA2175971
Date of Issue30/12/03
Date of Expiry07/05/16
Drug Interactionamyl nitrite / sodium nitrite / sodium thiosulfate
TargetUric acid
Information of corresponding available drug in the market
Brand NameElitek
CompanySanofi-Synthelabo Inc
Brand DiscriptionElitek is a recombinant urate-oxidase produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus. Rasburicase is a tetrameric protein with identical subunits. Each sub
Prescribed forUsed for preventing high blood levels of uric acid from occurring in patients with certain types of cancer (eg, leukemia, lymphoma, solid malignant tumors) who are receiving cancer chemotherapy treatment.
Chemical NameN.A.
FormulationElitek is supplied in 3 mL and 10 mL colorless, glass vials containing rasburicase at a concentration of 1.5 mg/mL after reconstitution. Elitek 1.5 mg presentation contains 1.5 mg rasburicase, 10.6 mg mannitol, 15.9 mg L-alanine, between 12.6 and 14.3 mg
Physcial AppearanceSterile, white to off-white, lyophilized powder
Route of AdministrationIntravenous administration
Recommended DosageThe recommended dose of Elitek is 0.2 mg/kg as a 30 minute Intravenous infusion daily for up to 5 days. Dosing beyond 5 days or administration of more than one course is not recommended.
ContraindicationPateints with history of anaphylaxic or severe hypersensitivity
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; blue or gray skin color; chest pain; chills; coughing up blood; dark urine; fever; irregular heartbeat; numbness or tingling of the skin; persistent sore throat; severe dizziness; shortness of breath, trouble breathing, or wheezing; swelling of the hands or feet; weakness; yellowing of the eyes and skin.
Useful Linkhttp://www.elitek.us
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 2
(2) Primary information
ID1306
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution75.8 to 138 mL/kg [adult patients]
ClearanceN.A.
CategoriesAntihyperuricemic Agents
Patents NumberCA2148537
Date of Issue16/07/02
Date of Expiry03/05/15
Drug InteractionCitanest Forte (epinephrine / prilocaine)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationIndividulas deficient in glucose -6-phosphate dehydrogenase.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/cdi/elitek.html
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 3
(3) Primary information
ID1307
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionCitanest HCl Plain (prilocaine)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/elitek-drug.htm
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 4
(4) Primary information
ID1308
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionCyanide Antidote Kit (amyl nitrite / sodium nitrite / sodium thiosulfate)
TargetN.A.
Information of corresponding available drug in the market
Brand NameFasturtec
CompanyN.A.
Brand DiscriptionFasturtec is a medicine that contains the active substance rasburicase. It is a recombinant urate-oxidase enzyme produced by genetically modified Saccharomyces cerevisiae strain. Rasburicase is a tetrameric protein with identical subunits of a molecular
Prescribed forFasturtec is used to treat and prevent high levels of uric acid in the blood in order to prevent kidney failure. It is used in adults and children with blood cancers who are at risk of a sudden rise in uric acid levels when they start to receive chemother
Chemical NameN.A.
FormulationN.A.
Physcial AppearancePowder and solvent that are made upto make solution.
Route of AdministrationIntravenous administartion
Recommended DosageThe recommended dose is 0.2 mg per kilogram body weight in both children and adults, given as a daily infusion for up to seven days. The duration of treatment is adjusted depending on the patient’s blood levels of uric acid and the doctor’s judgment.
ContraindicationHypersensitivity
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; blue or gray skin color; chest pain; chills; coughing up blood; dark urine; fever; irregular heartbeat; numbness or tingling of the skin; persistent sore throat; severe dizziness; shortness of breath, trouble breathing, or wheezing; swelling of the hands or feet; weakness; yellowing of the eyes and skin.
Useful Linkhttp://www.ncbi.nlm.nih.gov/pubmed/15493120
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 5
(5) Primary information
ID1309
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionEmla (lidocaine / prilocaine topical)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationPateint with a deficiency in glucose-6-phoshphate dehydrogenase or other metabolic disorder known to cause haemolytic anaemia.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/uk/fasturtec.html
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 6
(6) Primary information
ID1310
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionEmla Anesthetic Disc (lidocaine / prilocaine topical)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.medicines.org.uk/emc/medicine/4604
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 7
(7) Primary information
ID1311
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug Interactionepinephrine / prilocaine
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 8
(8) Primary information
ID1312
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug Interactionlidocaine / prilocaine topical
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 9
(9) Primary information
ID1313
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionNithiodote (sodium nitrite / sodium thiosulfate)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 10
(10) Primary information
ID1314
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionOraqix (lidocaine / prilocaine topical)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)


Entry 11
(11) Primary information
ID1315
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug Interactionsodium nitrite / sodium thiosulfate
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)